AbsoluteAI secures investment led by Sustainable Ventures to advance its drug discovery platform
Sustainable Ventures has led a funding round in AbsoluteAI to support core algorithmic development and pilot testing.
AbsoluteAI applies machine learning to streamline drug discovery while eliminating environmentally harmful compounds and reducing waste.
AbsoluteAI has secured funding led by Sustainable Ventures, alongside a group of angel investors, to support its drug discovery platform. The capital will be used to advance the company core algorithms, expand the team and complete further pilot testing prior to onboarding its initial clients.
The company develops machine learning software designed to screen out toxic compounds early in the pharmaceutical research process. By predicting mitochondrial toxicity and environmental outcomes, the technology aims to curb the high carbon emissions and resource waste associated with traditional drug development.
Use of funds
- 01Continue product development
- 02Grow the team
Investors
Categories
About the company
AbsoluteAI
AbsoluteAI builds machine learning algorithms to optimise drug discovery and minimise environmental waste.